COVID-19 Updates

Visit UC San Diego's Coronavirus portal for the latest information for the campus community.


​Phase-3 study targeting amyloid-beta in participants with mild cognitive impairment due to Alzheimer's disease or mild Alzheimer's disease. Please note that this is a re-dosing study that is only open to participants who were previously enrolled in the Aducanumab studies (221AD103, 221AD301, 221AD302, 221AD205).

​Biogen 221AD304
​Required Diagnosis
Alzheimer's disease
​126 wks (8 wks screening, 100 wks treatment period, 18 wks safety followup after the last dose)
​Lumbar Puncture
​Optional - 3 LPs (1 at screening, 2 during the treatment period)
​Amyloid PET
​Tau PET
For more information​

NIH Clinical Trials Website: